Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting

By afschroeder • December 5, 2025

Pasricha ND, Kim SK, Farooq AV, Lindgren ES, Yan R, Seitzman GD, Chan MF, Shantha JG, Skondra D, Jeng BH, Chamberlain WD, Colby KA, Goldstein DA, Sobrin L, Kim IK, Singh K, Chambers WA, Boyd WM, Silverstein J, Pohlmann PR, Lu J, Glencer AC, Huppert LA, Chien AJ, Rugo HS, Esserman LJ. Multicenter Interspecialty Consensus on Experimental Oncology Drug-Related Ocular Adverse Event Reporting. JAMA Ophthalmol. 2025 Dec 4. doi: 10.1001/jamaophthalmol.2025.3159. Epub ahead of print. PMID: 41343206.

Tags: Fellow, Hematology/Oncology, Publications

Related Posts

Promising New Platforms and Targets in the Management of Gastroesophageal Cancers

Yoon J, Chen CY, Watson R, Smyth E, Wainberg Z, Oh DY. Promising New Platforms and Targets in the Management of Gastroesophageal Cancers. Am Soc[...]

Expression of HER2 in the eye and the potential for on-target side effects with antibody-drug conjugates

Davenport S, Xie B, Hamblett K, Hausman D, Villalobos I, Singh HP, Cobrinik D, Hoon DSB, Zhou JY, Sibug-Saber M, Ma Y, Konecny GE, Heur[...]

Daraxonrasib in Previously Treated Advanced RAS-Mutated Pancreatic Cancer

Wolpin BM, Park W, Garrido-Laguna I, Spira A, Starodub A, Sommerhalder D, Punekar SR, Barve M, Pelster M, Herzberg B, Azad NS, Hecht JR, Ou[...]